We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+11.13%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
-$123M
Cap. Flow
-$193M
Cap. Flow %
-4.9%
Top 10 Hldgs %
32.83%
Holding
121
New
17
Increased
40
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
SGRY icon
Surgery Partners
SGRY
+$30.8M
2
LLY icon
Eli Lilly
LLY
+$24M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$20.7M
4
PHVS icon
Pharvaris
PHVS
+$20M
5
OSCR icon
Oscar Health
OSCR
+$18.8M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$163M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$89.3M
3
HUM icon
Humana
HUM
+$61.6M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$49.1M
5
BPMC
Blueprint Medicines
BPMC
+$32.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Consumer Staples 1.95%
3 Industrials 0.94%
4 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
26
Xenon Pharmaceuticals
XENE
$6.21B
$54.1M 1.37%
1,255,577
– –
AGL icon
27
Agilon Health
AGL
$1.63B
$53.9M 1.37%
353,400
+8,200
+2% +$1.36M
MRUS
28
DELISTED
Merus
MRUS
$51.6M 1.31%
1,146,560
+274,491
+31% +$11.1M
AGIO icon
29
Agios Pharmaceuticals
AGIO
$1.95B
$51.6M 1.31%
1,764,505
-387,668
-18% -$10.4M
HUM icon
30
Humana
HUM
$46.3B
$51.1M 1.3%
147,408
-162,592
-52% -$61.6M
MIRM icon
31
Mirum Pharmaceuticals
MIRM
$6.02B
$46.6M 1.18%
1,856,564
+5,100
+0.3% +$140K
IRTC icon
32
iRhythm Holdings
IRTC
$4.1B
$45.5M 1.16%
392,250
+41,500
+12% +$4.67M
SWAV
33
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$44M 1.12%
135,000
+15,000
+13% +$3.68M
ASND icon
34
Ascendis Pharma A/S
ASND
$16.8B
$43.8M 1.11%
290,000
– –
SRPT icon
35
Sarepta Therapeutics
SRPT
$1.81B
$42.4M 1.08%
327,600
– –
AZTA icon
36
Azenta
AZTA
$1.54B
$41.9M 1.06%
694,750
+187,250
+37% +$12M
OLK
37
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$39.4M 1%
1,676,500
– –
IMVT icon
38
Immunovant
IMVT
$8.24B
$37.2M 0.94%
1,150,123
+166,822
+17% +$6.09M
ACCD
39
DELISTED
Accolade Inc
ACCD
$37.1M 0.94%
3,540,000
+55,000
+2% +$625K
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$29B
$36.5M 0.93%
244,000
+9,000
+4% +$1.5M
AKRO
41
DELISTED
Akero Therapeutics
AKRO
$32.8M 0.83%
1,299,888
+218,824
+20% +$5.26M
OSCR icon
42
Oscar Health
OSCR
$8.54B
$31.4M 0.8%
2,110,000
+1,375,000
+187% +$18.8M
PCRX icon
43
Pacira BioSciences
PCRX
$974M
$30.8M 0.78%
1,055,500
– –
RVMD icon
44
Revolution Medicines
RVMD
$44.4B
$29.8M 0.76%
923,681
+198,529
+27% +$5.88M
LFST icon
45
Lifestance Health
LFST
$4.55B
$29.5M 0.75%
4,780,000
+245,000
+5% +$1.65M
SGRY icon
46
Surgery Partners
SGRY
$2.09B
$29.4M 0.75%
+985,000
New +$30.8M
WRBY icon
47
Warby Parker
WRBY
$3.26B
$28.3M 0.72%
2,080,000
+51,700
+3% +$686K
INZY
48
DELISTED
Inozyme Pharma
INZY
$28.2M 0.72%
3,681,174
– –
INSP icon
49
Inspire Medical Systems
INSP
$1.73B
$28M 0.71%
130,500
+31,500
+32% +$6.17M
LEGN icon
50
Legend Biotech
LEGN
$4B
$28M 0.71%
499,486
+7,042
+1% +$425K
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Rock Springs Capital Management held 121 positions worth $3.94B, down 3% from $4.06B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rock Springs Capital Management withdrew a net $193M in Q1 2024, closing 7 positions and reducing 11 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $163M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Surgery Partners worth $29.4M.

  • Rock Springs Capital Management's largest Q1 2024 buy was Surgery Partners: 985,000 shares worth $29.4M.
  • Rock Springs Capital Management added most to Eli Lilly in Q1 2024, an estimated $24M increase.
  • Rock Springs Capital Management's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $89.3M.
  • Rock Springs Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $163M.
  • Rock Springs Capital Management's ten largest holdings make up 33% of its $3.94B portfolio in Q1 2024.
  • Rock Springs Capital Management opened 17 new positions and closed 7 in Q1 2024.
  • Rock Springs Capital Management's portfolio value fell 3% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q1 2024, filed 15 May 2024.